Aptose Biosciences completes C$8 million share offering

Date Closed

December 10, 2013

Lead Office

Québec City


8.00 Million CAD

On December 10, 2013, Aptose Biosciences completed its bought deal public offering of common shares.

The Company issued a total of 12,730,000 Offered Shares at C$0.55 per Offered Share, for aggregate gross proceeds of C$7 million. The Offering was sold to a syndicate of underwriters co-led by Clarus Securities Inc. and Canaccord Genuity Corp., and including Jennings Capital Inc. and D&D Securities Inc. and  PowerOne Capital Markets Limited as a member of the selling group, upon the terms of an underwriting agreement entered into among the Company and the Underwriters. In addition, the Company  granted the Underwriters an over-allotment option to purchase that number of additional common shares equal to 15% of the Offered Shares sold pursuant to the Offering at the Offering Price for a period ending 30 days following the closing of the Offering (the Over-Allotment Option).

On January 8, 2014, Aptose Biosciences announced that the underwriters exercised in full their over-allotment option to purchase an additional 1,909,500 common shares of the Company at C$0.55 per common share. As a result of the exercise of this over-allotment option, Aptose received additional gross proceeds of C$1 million and will have raised total gross proceeds of C$8 million from its public offering.

Aptose Biosciences, headquartered in Toronto, is a biopharmaceutical company focused on the discovery, research and development of anti-cancer therapies.

McCarthy Tétrault LLP represented Lorus Therapeutics, the issuer, with a team led by Charles-Antoine Soulière and including Myreille Gilbert, Annie Mailhot-Gamelin, Ian Michael and Jacob Stone.